Hikma Outlines Strategy For Coping With COVID-19 Demand
US Propofol Launch Addresses Shortage Amid Higher Injectables Demand Overall
As Hikma launches propofol vials in three presentations in the US to address a local shortage, CEO Siggi Olafsson explains how the company is more broadly keeping on top of the higher demand generated by the coronavirus pandemic.
You may also be interested in...
Hikma says it is prioritizing the production and delivery of medicines that are in the highest demand amid the COVID-19 pandemic, as the firm has provided a trading update that maintains its sales forecasts in the face of “challenging market conditions” and uncertainty.
Extra capacity coming online at a high-containment facility in Portugal is opening up opportunities for Hikma to expand its presence in Europe’s injectables market.
A CJEU advocate general has backed a European Commission fine of almost €94m imposed on Lundbeck over “pay for delay” deals struck with four generics firms over citalopram.